### Subject Index

**No. 7, July 2004, 479–558**

- anti-hypertensive therapy, stroke survivors in southern Africa 503–508
- anti-tuberculous drugs
- DOTS, in China 716
- free, for developing countries 79
- public–private mix for DOTS implementation 580–586
- spread of resistance in Europe and Asia 313
- antibiotics (antimicrobials)
- for childhood illness, training health workers 509–515
- maternal syphilis 401, 433–438
- resistance containment and surveillance approach 928–934
- antimalarial drugs
- costs of effective, in Africa 381–384
- see also artesinin combination therapy
- antiretroviral therapy
- de-listing of approved generic drugs 633, 718
- feasibility of scale-up, in Africa 798–800
- preparedness 959
- survival of HIV-infected adults in Africa 462–469
- arthritis, patient advocacy and 115–120
- Asia, drug-resistant TB 313
- asthma, in early childhood, in Brazil 516–522
- Australia, nurse migration to 587–594

**No. 6, June 2004, 399–478**

- The anthrax letters: a medical detective story (Cole) 71–72
- anti-tuberculous drugs
- DOTS, in China 716
- free, for developing countries 79
- public–private mix for DOTS implementation 580–586
- spread of resistance in Europe and Asia 313
- antibiotics (antimicrobials)
- for childhood illness, training health workers 509–515
- maternal syphilis 401, 433–438
- resistance containment and surveillance approach 928–934
- antimalarial drugs
- costs of effective, in Africa 381–384
- see also artesinin combination therapy
- antiretroviral therapy
- de-listing of approved generic drugs 633, 718
- feasibility of scale-up, in Africa 798–800
- preparedness 959
- survival of HIV-infected adults in Africa 462–469
- arthritis, patient advocacy and 115–120
- Asia, drug-resistant TB 313
- asthma, in early childhood, in Brazil 516–522
- Australia, nurse migration to 587–594

**No. 5, May 2004, 319–398**

- The anthrax letters: a medical detective story (Cole) 71–72
- anti-tuberculous drugs
- DOTS, in China 716
- free, for developing countries 79
- public–private mix for DOTS implementation 580–586
- spread of resistance in Europe and Asia 313
- antibiotics (antimicrobials)
- for childhood illness, training health workers 509–515
- maternal syphilis 401, 433–438
- resistance containment and surveillance approach 928–934
- antimalarial drugs
- costs of effective, in Africa 381–384
- see also artesinin combination therapy
- antiretroviral therapy
- de-listing of approved generic drugs 633, 718
- feasibility of scale-up, in Africa 798–800
- preparedness 959
- survival of HIV-infected adults in Africa 462–469
- arthritis, patient advocacy and 115–120
- Asia, drug-resistant TB 313
- asthma, in early childhood, in Brazil 516–522
- Australia, nurse migration to 587–594

**No. 4, April 2004, 239–318**

- The anthrax letters: a medical detective story (Cole) 71–72
- anti-tuberculous drugs
- DOTS, in China 716
- free, for developing countries 79
- public–private mix for DOTS implementation 580–586
- spread of resistance in Europe and Asia 313
- antibiotics (antimicrobials)
- for childhood illness, training health workers 509–515
- maternal syphilis 401, 433–438
- resistance containment and surveillance approach 928–934
- antimalarial drugs
- costs of effective, in Africa 381–384
- see also artesinin combination therapy
- antiretroviral therapy
- de-listing of approved generic drugs 633, 718
- feasibility of scale-up, in Africa 798–800
- preparedness 959
- survival of HIV-infected adults in Africa 462–469
- arthritis, patient advocacy and 115–120
- Asia, drug-resistant TB 313
- asthma, in early childhood, in Brazil 516–522
- Australia, nurse migration to 587–594

**No. 3, March 2004, 160–238**

- The anthrax letters: a medical detective story (Cole) 71–72
- anti-tuberculous drugs
- DOTS, in China 716
- free, for developing countries 79
- public–private mix for DOTS implementation 580–586
- spread of resistance in Europe and Asia 313
- antibiotics (antimicrobials)
- for childhood illness, training health workers 509–515
- maternal syphilis 401, 433–438
- resistance containment and surveillance approach 928–934
- antimalarial drugs
- costs of effective, in Africa 381–384
- see also artesinin combination therapy
- antiretroviral therapy
- de-listing of approved generic drugs 633, 718
- feasibility of scale-up, in Africa 798–800
- preparedness 959
- survival of HIV-infected adults in Africa 462–469
- arthritis, patient advocacy and 115–120
- Asia, drug-resistant TB 313
- asthma, in early childhood, in Brazil 516–522
- Australia, nurse migration to 587–594

**No. 2, February 2004, 82–159**

- The anthrax letters: a medical detective story (Cole) 71–72
- anti-tuberculous drugs
- DOTS, in China 716
- free, for developing countries 79
- public–private mix for DOTS implementation 580–586
- spread of resistance in Europe and Asia 313
- antibiotics (antimicrobials)
- for childhood illness, training health workers 509–515
- maternal syphilis 401, 433–438
- resistance containment and surveillance approach 928–934
- antimalarial drugs
- costs of effective, in Africa 381–384
- see also artesinin combination therapy
- antiretroviral therapy
- de-listing of approved generic drugs 633, 718
- feasibility of scale-up, in Africa 798–800
- preparedness 959
- survival of HIV-infected adults in Africa 462–469
- arthritis, patient advocacy and 115–120
- Asia, drug-resistant TB 313
- asthma, in early childhood, in Brazil 516–522
- Australia, nurse migration to 587–594

**No. 1, January 2004, 1–81**

- The anthrax letters: a medical detective story (Cole) 71–72
- anti-tuberculous drugs
- DOTS, in China 716
- free, for developing countries 79
- public–private mix for DOTS implementation 580–586
- spread of resistance in Europe and Asia 313
- antibiotics (antimicrobials)
- for childhood illness, training health workers 509–515
- maternal syphilis 401, 433–438
- resistance containment and surveillance approach 928–934
- antimalarial drugs
- costs of effective, in Africa 381–384
- see also artesinin combination therapy
- antiretroviral therapy
- de-listing of approved generic drugs 633, 718
- feasibility of scale-up, in Africa 798–800
- preparedness 959
- survival of HIV-infected adults in Africa 462–469
- arthritis, patient advocacy and 115–120
- Asia, drug-resistant TB 313
- asthma, in early childhood, in Brazil 516–522
- Australia, nurse migration to 587–594
financial challenges and GAVI 697–702
reporting of adverse events following, in Europe 828–835
through public–private partnership, in Cambodia 661–667
variation in cost of delivery, in Peru 676–682
see also vaccination
Immunization essentials: a practical field guide (USAID) 709
Immunization financing in developing countries and the international vaccine market: trends and issues (Asian Development Bank) 710–711
immunoglobulin deficiencies, poliovirus carrier status 3–8
income, quality of life and, in South Africa 206–212
India
ban on smoking in public places 473
clinical trials without ethical review 314
continuing medical education (CME) 154–155
counters to brain drain 608–615
de-listing of approved generic AIDS drugs 633, 718
public–private mix for DOTS implementation 580–586
rubella sero-surveys at three eye hospitals in Tamil Nadu 259–264
TB in tribal population of Car Nicobar 836–843
Indonesia
hepatitis B vaccine freezing in cold chain 99–105
respiratory syncytial virus infection 914–922
infant mortality
Millennium Development Goals 804
risk factors in rural Burkina Faso 265–273
infants
HIV-infected mothers
cotrimoxazole prophylaxis 290–298
feeding 161
recommended replacement milks, in South Africa 164–171
newborn see neonates
respiratory syncytial virus infection 914–922
signs and symptoms of illness, in Kenya 322–329
see also children
infectious diseases see communicable diseases
influenza
avian 236–237, 242
pandemics, preparedness for 242, 317–318, 959
information dissemination, Cochrane Collaboration 778–783
information technology
in primary health care in developing countries 867–874
public health contribution of e-Health 800–802
informed consent, in developing countries 771–777
injuries, care services 241
insecticide-treated nets (ITNs) for malaria control 84
child mortality impact in West Africa 85–91
longer-lasting 884–886
Integrative Management of Childhood Illness, Multi-Country Evaluation 509–515
intellectual property rights see patents
international aid
Bam earthquake survivors 156
Caribbean after series of hurricanes 883–884
earmarked donor funding 703–708
global priorities 554–555
Millennium Development Goals and 947–952
in Sudan 233–234, 553–554
International Classification of Diseases (ICD) coding changes, cause-specific mortality trends and 904–913
International Committee of the Red Cross (ICRC), latrine revision programme 319
International Health Regulations 959
International Organization for Migration 561
International Standard Randomised Controlled Trial Number (ISRCTN) register 321, 397
intestinal helminthiases
control in children in Cambodia 636
control with ivermectin 562, 563–571
Ivan, help for Bam earthquake survivors 156
Iraq, mental health priorities 555
Ireland
ban on smoking in workplace 391–392
nurse migration to 587–594
ivermectin
adverse effects 562, 566
mass treatment in Brazil 562, 563–571
jaundice, herbal treatment 154
journals, scientific
enhancing health research in developing countries 163, 226–228
gender and poverty and published research 740–745
MMR vaccine safety and publication ethics 311–312
publication of research from developing countries 802–803
US trade embargo ruling 312, 394
Kenya
antenatal syphilis control programme 410–416
public–private mix for DOTS implementation 580–586
signs and symptoms of illness in infants 322–329
*know–do* gap, bridging 723, 724–723, 959
antenatal care in Thailand 746–749
policy development in Thailand 750–756
role of e-Health 800–802
knowledge
management, Cochrane Collaboration and 778–783
ownership, patents in pharmaceutical R&D 784–790
laboratory
containment, wild poliovirus 59–66
diagnosis of measles in low-transmission settings 852–857
SARS safety concerns 470
Lao People’s Democratic Republic, thalassaemia and haemoglobin E screening 364–372
Latin America, TRIPS agreement and public health 815–821
latrine revision programme, in Afghanistan 281–289
Lebanon, population ageing 219–225
leprosy, scenario analysis 373–380
leptospirosis, genomics breakthrough 471–472
Liberia, yellow fever emergency 233
life expectancy, smokers 632–633
low-income countries see developing countries
M
macroeconomics and health, WHO commission 957–958
macular degeneration, global data for 2002 844–851
malaria
artemisinin combination therapy see artemisinin combination therapy
averting a disaster in Africa 381–384
criticisms of WHO treatment policy 237
DOT for control 472–473
economics of international aid 554–555
insecticide-treated nets for control 84, 85–91, 884–886
monkey, spread to humans 392–393
Malawi, cotrimoxazole prophylaxis in HIV-positive TB patients 354–363
Malaysia, monkey malaria in humans 392–393
Mali
female genital mutilation 153–154
polio cases 717
Manual of basic techniques for a health laboratory, 2nd edition (WHO) 229
marital status, family-planning service provision and 180–186
maternal death
infant and child mortality after, in rural Burkina Faso 265–273
new WHO initiative 810
measles
laboratory diagnosis in low-transmission settings 852–857
mumps and rubella (MMR) vaccine, safety concerns in UK 311–312
outbreaks in Europe 889–890
prospect for global eradication 134–138
reduction in global death toll 394
mebendazole, mass treatment in Brazil 563–571
media groups, Global Media AIDS Initiative 232–233
medical education, continuing (CME), in India 154–155
medicinal plants
use by indigenous communities in Bolivia 243–250
see also herbal medicines
men, risk factors for sexual violence against intimate partners 330–337
meningitis, rare strain in Burkina Faso 398
mental health
care, treatment gap 858–866
priorities in Iraq 555
research in developing countries, role of scientific journals 226–228
in south-eastern Europe 539–546
two new reports 810
Mexico
poliovirus carrier status in primary immune deficiency disorders 3–8

microbicides, topical anti-HIV 393–394
micronutrient deficiencies, global damage assessment 230–231
migration
and health 561
health-care workers 560, 595–600, 601–607, 634, 797–798
nurses; trends and policies 587–594
patterns of physicians and nurses in 1970s 624–630
strategies to discourage 608–615, 616–623
milk substitutes, for infants of HIV-infected mothers 164–171
Millennium Development Goals (MDG)
achieving 947–952
sanitation targets 234–235
tuberculosis control update 889
updates on progress 156–157, 804–806
mineral deficiencies, global damage assessment 230–231
mortality
diabetes and climate change 481
statistics, data sources, in developing countries 83
trends, impact of ICD coding changes 904–913
mosquitoes
DDT for control 472–473
insecticide-treated nets see insecticide-treated nets (ITNs) for malaria control
Mozambique
respiratory syncytial virus infection 914–922
secondary prevention of stroke 503–508
N
neonates
congenital syphilis management 424–430
supplementary immunization to prevent tetanus, in Pakistan 643–651
Nepal, public–private partnership to control TB 92–98
Netherlands, ICD coding changes and cause-specific mortality trends 904–913
Nigeria
health research influencing political manifestos 75
polio vaccine safety 313
respiratory syncytial virus infection 914–922
resumption of polio immunization 633, 717
non-profit organizations, tackling neglected diseases 395–396
noncommunicable diseases
mortality in Russian Federation 875–880
new global strategy 536
nongovernmental organizations
DOTS implementation for TB control 580–586
immunization provision, in Cambodia 661–667
participation in health research 757–763
Norway
ICD coding changes and cause-specific mortality trends 904–913
nurse migration to 587–594
Novartis, free anti-TB drug supplies 79
nurses, migration of
from developing countries 595–600
patterns in 1970s 624–630
and policies 587–594
O
obesity
childhood 959
and socioeconomic status, in developing countries 940–946
obcessive compulsive disorders (OCD), treatment gap 858–866
opportunistic infections, HIV-infected adults in Africa 462–469
oral contraception pill, for contraception within marriage 180–186
oral diseases, in developing countries 238
oral rehydration solutions, cost-effectiveness in developing countries 523–531
organ trafficking and transplantation 715
osmotic fragility (OF) test, thalassemia and haemoglobin E screening 364–372
P
pain relief 889
Pakistan, supplementary tetanus immunization 643–651
Pan American Health Organization (PAHO)
measles eradication strategy 852–857
restoration of health services in Haiti 316–317
parallel imports, TRIPS agreement and 815–821
parasitic diseases
treatment in children in Cambodia 636
ivermectin mass treatment 563–571
paratyphoid fever, global burden 346–353
patents
genomics knowledge and equity 385–389
role in pharmaceutical R&D 784–790
TRIPS agreement 813, 815–821
patients
acceptance of priority-setting criteria, in Uganda 172–179
advocacy, and arthritis 115–120
enhancing health service utilization, in Burkina Faso 572–579
evaluations, vs WHO measures of achievement 106–114
fixed-dose combination pills vs unit-of-use packaging and adherence 935–939
penicillin, maternal syphilis 401, 433–438
pemethrin, residual spraying against Triatoma infestans, in Argentina 196–205
Peru
costs of delivery of routine immunization 676–682
reproductive tract infections in rural women 483–492
pharmaceutical agents see drugs
pharmaceutical industry
registration of clinical trials 714
role of patents in R&D 784–790
noncommunicable disease control in Russian Federation 875–880
nurse migration 587–594
religion-based health 923–927
response to health inequalities 482
polio(omyelitis)
cases in Africa 394, 557, 717
eradication 1
certification process and lessons learned 24–30
economics 683–688
news on progress 157, 237–238, 557
photographs 67–70
volunteers’ contribution 2
post-certification era 1
cost analysis of immunization policies 9–15
framework for evaluating risks of paralytic polio 40–46
immunization strategies in developing countries 53–58
polio control measures 47–52
role of routine vaccination 31–39
vaccination
campaigns 237–238, 889, 890
in post-certification era see above
resumption in Nigeria 633, 717
vaccine-associated paralytic current state of knowledge 16–23
developing country perspective 53–58
poliovirus
carrier status, primary immune deficiency disorders 3–8
circulating vaccine-derived 16–23
containment, and global certification 59–66
poliovirus vaccines
inactivated (IPV)
cost analysis 9–15
in developing countries 53–58
in post-certification era 31–39, 47–52
production site containment 59–66
oral (OPV)
cost analysis 9–15
in developing countries 53–58
in post-certification era 31–39, 47–52
safety, in Nigeria 313
population ageing
global dependency and dependency ratios and 251–258
in Lebanon 219–225
postmarketing surveillance, vaccines 828–835
Index

surveillance
  antimicrobial resistance 928–934
second-generation approach to HIV 121–127
Sweden, ICD coding changes and cause-specific mortality trends 904–913
syphilis
  congenital 401
  antenatal control; people, programmes, policies and politics 417–423
case studies of control programmes 410–416
talc control in HIV/AIDS era 431–432
diagnostic tools for preventing 439–446
economic and programmatic aspects of prevention 402–409
recommendations for prevention and management 424–430
effectiveness of condoms in preventing 454–461
maternal
diagnostic tools for managing 439–446
pathophysiology and treatment 433–438
women in rural Peru 483–492

T
Tanzania see United Republic of Tanzania
Terrorism and public health: a balanced approach to strengthening systems and protecting people (Levy & Sidel) 72
tetanus, supplementary maternal immunization in Pakistan 643–651
Thailand
  antenatal care 746–749
  bridging the “know–do” gap 723
HIV/AIDS vaccine trial 231
diagnostic tools 750–756
thalassaemia and thalassemia screening 364–372
3-by-5 strategy, to combat AIDS/HIV in developing countries 77–78, 474–476
tobacco control
  bans on smoking in public places 391–392, 473
  religion-based interventions 894, 923–927
WHO Framework Convention 635
toilet facilities, revision programme, in Afghanistan 281–289
trachoma, global data for 2002 844–851
Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement 813, 815–821
traditional medicine
guidelines 635–636
use by indigenous communities in Bolivia 243–250
training
  health researchers in developing countries 764–770
  health workers to use antimicrobials in childhood illness 509–515
  transplantation, and organ trafficking 580–586
  WHO Quality of Life questionnaire (WHOQOL-100), chronic disease and wheezing conditions in early childhood, in Brazil 516–522
restoration of health services, in Haiti 316–317
Tonga, restoration of health services 316–317
Toros, status in primary immune deficiency disorders 3–8
trajectories of control programmes 318–319
TRIPS Agreement 813, 815–821

U
Uganda
  crisis in region neighbouring Darfur 886
  determinants of personal demand for AIDS vaccine 652–660
  discontinuation of cost sharing 187–195
natural history of HIV infection 462–469
setting priorities for health care 172–179
training health workers to use antimicrobials in childhood illness 509–515
UNAIDS
  joint HIV-TB action 810
  recommended replacement milks for infants of HIV-infected mothers 164–171
United Kingdom (UK)
  ICD coding changes and cause-specific mortality trends 904–913
  MMR vaccine safety controversy 311–312
  nurse migration to 587–594
  poliovirus carrier status in primary immune deficiency disorders 3–8
United Nations (UN)
  Global Media AIDS Initiative 232–233
  Millennium Development Goals 947–952
  proposed treaty on human cloning 76
United Nations Children’s Fund (UNICEF)
  promotion of breastfeeding 318
  recommended replacement milks for infants of HIV-infected mothers 164–171
United Republic of Tanzania
  training health workers to use antimicrobials in childhood illness 509–515
  zinc as adjunct therapy for childhood diarrhoea 523–531
United States (USA)
  HIV/AIDS vaccine trial in Thailand and 231
  nurse migration to 587–594
  poliovirus carrier status in primary immune deficiency disorders 3–8
  strategies to discourage brain drain 616–623
  trade embargos affecting scientific publishing 312, 394
universal coverage, implementation in Thailand 750–756
urban areas, public–private partnership to control TB 92–98
user fees see cost sharing

V
vaccination
  campaign, in Americas 398
  economics, in developing countries 640, 689–696
  see also immunization
The vaccine book (Bloom & Lambert) 709–710
vaccines
  for developing countries, regulatory pathways 128–133
  reporting of adverse reactions, in Europe 828–835
vaginal discharge, women in rural Peru 483–492
Viet Nam, public–private mix for DOTS implementation 580–586
visual impairment, global data for 2002 844–851
vitamin deficiencies, global damage assessment 230–231
voluntary sector, role in polio eradication 2

W
wars and conflicts
  humanitarian crisis in Sudan 233–234
  mental health priorities in Iraq 555
restoration of health services, in Haiti 316–317
visual impairment, global data for 2002 844–851
wheezing conditions in early childhood, in Brazil 516–522
WHO Quality of Life questionnaire (WHOQOL-100), chronic disease and caregivers in China 493–502
women
  discrimination against, and HIV/AIDS control 812
  equity of health research and 740–745
  human rights in Sudan 233–234
  mental health priorities in Iraq 555
  rehabilitation of health services, in Haiti 316–317
  sexual violence by intimate partners, in South Africa 330–337
  topical anti-HIV microbicides 393–394
World Alliance for Patient Safety 889, 892
World Health Assembly 2004 478
World Health Organization (WHO)
  certification of polio eradication 24–30
  health system performance measures, vs patient evaluations 106–114
World health report 2003 78–79
World health report 2004 477–478
World Report on Knowledge for Better Health: Strengthening Health Systems 959
World Report on road traffic injury prevention (WHO and World Bank) 240
  315–316
World Trade Organization (WTO) 813, 815–821

Y
yellow fever, emergency in Liberia 233
young people, unmarried, attitudes to provision of sexual and reproductive health services, in China 274–280

Z
Zimbabwe, red AIDS ribbon banned 633
zinc, as adjunct therapy for childhood diarrhoea 523–531
zoonoses, role of human behaviour in emergence 478
| Author Index |

Luby, SP 346
Lumbiganon, P 746
Lydon, P 697

M
Mahoney, RT 709–710
Maia, MFS 867
Majiyagbe, J 2
Makela, PH 828
Malema, S 354
Malla, P 92
Maman, S 299
Mandelbaum-Schmid, J 153–154,
Malla, P 92
Malema, S 354
Mäkelä, PH 828
Majiyagbe, J 2
Maia, MFS 867
Mahoney, RT 709–710
Lydon, P 697
Lumbiganon, P 746
Luby, SP 346

N
Nabarro, D 642
Nakyanzi-Mugisha, MV 381
Nanthanrad, K 259
Nathanson, N 16
Nayyar, A 417
Nofal, F 431
Nebié, I 85
Nelson, CM 99
Ngama, M 323
Nitayaramphong, S 750

Nohynek, H 828
Norheim, OF 172
Novotny, T 875
Nulli-Karp, C 715, 804–805, 886,
957–958

O
Oblapenko, G 47
Obot, I 390
Ochola, S 381
Odaiibo, GN 914
Olayeke, DO 914
Olin, P 828
Oliva, MA 815
Olof, A 381
Opliger, A 281
O'Reilly, K 410
Ostlon, P 740

P
Pablos-Mendez, A 720
Page, SW 955
Pallarschi, MA 3, 16
Pande, SB 92
Pang, T 720
Papakasis, PC 164
Pararajasegaram, R 844
Panyi, G 187, 509, 652
Pascolini, D 844
Pastila, S 828
Patel, RS 552
Pathania, V 580
Patz, JA 481
Peeling, RW 439
Penn, ME 676
Peshu, N 323
Philip, P 892
Piner, JF 281
Pinto, J 3
Pokharel, GP 844
Polio Project Team 3
Popkin, BM 940
Powles, J 150–151
Prajna, L 259
Prakash, K 259
Premji, Z 381
Purnwanto, H 99

Q
Quddus, A 643

R
Rafter, N 935
Ravindran, M 259
Rehle, T 121
Reichenbach, L 417
Resnikoff, S 844
Richards, JH 373
Robberstad, B 523
Robertson, K 778
Robertson, SE 259, 914
Roca, A 914
Rodgers, A 935
Rollins, NC 164
Ronald, LA 281
Rota, J 852
Rudan, I 895
Ruger, JP 951

S
Sabatinegli, G 642
Sabin, LL 290
Sachs, JD 947
Sae-ung, N 364
Sales de Oliveira, FA 563
Salisbury, DM 57
Salomon, OD 196
Salojee, H 424
Sanca, S 243
Sanchaisuriya, K 364
Sanders, D 757, 952
Sanders, R 59
Sanderson, CBF 676
Sangrueje, N 9
Saracero, B 858
Saravia, NG 608
SASPI project team 503
Sauerborn, R 572
Saviodoff, WD 139, 950
Saxena, P 219
Saxena, S 390, 858
Sayer, AA 251
Schatzmayr, HG 65
Schellenberg, JA 509
Schimdt, G 402
Schmid, K 621
Schoub, BD 63
Schwalbe, N 539
Schwartz, JB 661
Segura, EL 196
Sehgal, SC 836
Semi, L 243
Sen, G 740
Sen, K 219
Shah, IH 180
Shimizu, H 16
Shisana, O 812
Shukshin, A 391
Sibai, AM 83, 219
Siegnfried, N 778
Simoes, EAF 914
Simonsen, GS 928
Singer, PA 385
Sixma, HJ 106
Smith, J 24
Smith, PG 462
Smith, RD 385
Smith, J 24
Smith, PG 462
Smith, RD 385
Smith, WCS 373
So, AD 813
Sodhaliski, J 587
Sommerfelt, H 523
Speare, R 562
Spillmann, C 196
Starido, R 196
Steen, R 424
Stilwell, B 560, 595
Stoehr, K 242
Strand, T 523
Summan, H 707
Sutch, S 550–551
Sutter, R 3
Sutter, RW 31, 47
Sylla, M 338

T
Talbot, EA 928
Tangarcharonsathien, V 750
Tangermann, RH 24
Tanner, M 893
Tapsall, JW 928
Tegang, S-P 668
Temmerman, M 431
Tham, J 290
Thorsteinsdóttir, H 385
Tomaskovic, L 895
Tomasi, E 867
Tomkowskij, L 895
Tran, N 668
Tu, X 274
Turnbull, P 71–72
Twisselmann, B 71

U
Uchtenhagen, A 641
Uplekar, M 580
Utzinger, J 954

V
Van Damme, P 243
Van der Eijk, J 106
Van Loon, AM 63
Van Oortmerssen, GI 373
Van Puyvelde, L 243
Vandeloo, I 243
Vega, J 482
Velaphi, S 424
Velásquez, G 815
Venter, M 914
Vijayalakshmi, P 259
Villar, J 802
Vonkmk, J 778
vonHm, B 381
Vujicic, M 595

W
Wabwire-Mangen, F 187
Waddington, C 703
Wald, A 447
Walgate, R 74–75
Walker, D 676
Walker, DG 401
Walker, GL 401
Wang, MD 547
Waters, HR 668
Weaver, M 447, 454
Webster, ADB 3
Wheelan, A 619
Whitle, H 462
Whitty, CMJ 381
Whitworth, J 462
Wibisono, H 99
Wibulpholprasert, S 750
Widjava, A 99
Wickie, T 563
Winijakul, N 746
Winkelstein, J 3
Winter, B 563
Wise, J 884–886
Wiseman, V 381
Wynsorge, CS 668
Wolfe, ND 668
Wolf, C 29
Wolfson, LJ 643
Wright, PF 16, 914

X
Xiao, S 493

Y
Yach, D 308–309
Ye, H 431, 439
Young, D 493
Younis, M 643

Z
Zhou, L 493
Zhou, X 493
Zhu, Y 914
Zimmer, M 713
Zurn, P 595